Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cencora ( (COR) ) is now available.
On December 15, 2025, Cencora announced its agreement to acquire the majority of equity interests in OneOncology from TPG for approximately $3.6 billion, with a total cash consideration of $5.0 billion including debt retirement. This acquisition aligns with Cencora’s pharmaceutical-centric strategy, aiming to enhance its specialty solutions, strengthen its market leadership, and improve patient access to pharmaceuticals. The transaction, expected to close by the end of fiscal 2026 Q2, will be funded through new debt financing, with Cencora maintaining its investment-grade credit rating. The acquisition is anticipated to be neutral to Cencora’s adjusted diluted EPS in the first year post-close, and the company has raised its long-term guidance expectations to reflect OneOncology’s contribution to growth.
The most recent analyst rating on (COR) stock is a Hold with a $363.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
Cencora’s overall stock score is driven by strong financial performance and positive earnings call sentiment, indicating a solid growth outlook. However, technical indicators suggest bearish momentum, and the high P/E ratio raises valuation concerns. Corporate events provide additional support through strategic financial flexibility.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora is a leading global pharmaceutical solutions organization focused on enhancing the lives of people and animals worldwide. The company collaborates with pharmaceutical innovators to optimize market access to therapies, providing secure and reliable delivery of pharmaceuticals and healthcare products. Cencora boasts a workforce of over 51,000 employees and is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with annual revenues exceeding $300 billion.
Average Trading Volume: 1,541,942
Technical Sentiment Signal: Buy
Current Market Cap: $67.12B
For an in-depth examination of COR stock, go to TipRanks’ Overview page.